BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38569942)

  • 1. Disrupting glycolysis and DNA repair in anaplastic thyroid cancer with nucleus-targeting platinum nanoclusters.
    Pan Z; Lu X; Hu X; Yu R; Che Y; Wang J; Xiao L; Chen J; Yi X; Tan Z; Li F; Ling D; Huang P; Ge M
    J Control Release; 2024 May; 369():517-530. PubMed ID: 38569942
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tolfenamic acid induces apoptosis and growth inhibition in anaplastic thyroid cancer: Involvement of nonsteroidal anti-inflammatory drug-activated gene-1 expression and intracellular reactive oxygen species generation.
    Chang JW; Kang SU; Choi JW; Shin YS; Baek SJ; Lee SH; Kim CH
    Free Radic Biol Med; 2014 Feb; 67():115-30. PubMed ID: 24216474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alantolactone induces concurrent apoptosis and GSDME-dependent pyroptosis of anaplastic thyroid cancer through ROS mitochondria-dependent caspase pathway.
    Hu Y; Wen Q; Cai Y; Liu Y; Ma W; Li Q; Song F; Guo Y; Zhu L; Ge J; Zeng Q; Wang J; Yin C; Zheng G; Ge M
    Phytomedicine; 2023 Jan; 108():154528. PubMed ID: 36343549
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
    Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
    Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CRSP8 promotes thyroid cancer progression by antagonizing IKKα-induced cell differentiation.
    Liao Y; Hua Y; Li Y; Zhang C; Yu W; Guo P; Zou K; Li W; Sun Y; Wang R; Zuo Y; Sui S; Tian C; Hao J; Chen M; Hu S; Chen M; Long Q; Wang X; Zou L; Xie F; Guo W; Deng W
    Cell Death Differ; 2021 Apr; 28(4):1347-1363. PubMed ID: 33162555
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ym155 Induces Oxidative Stress-Mediated DNA Damage and Cell Cycle Arrest, and Causes Programmed Cell Death in Anaplastic Thyroid Cancer Cells.
    Xu Q; Mackay RP; Xiao AY; Copland JA; Weinberger PM
    Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33669447
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KLF5 influences cell biological function and chemotherapy sensitivity through the JNK signaling pathway in anaplastic thyroid carcinoma.
    Wang Z; Qiu X; Zhang H; Li W
    J Biochem Mol Toxicol; 2020 May; 34(5):e22469. PubMed ID: 32173973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
    Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
    Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of a histone deacetylase inhibitor (PXD101) for thyroid cancer treatment.
    Lin SF; Lin JD; Chou TC; Huang YY; Wong RJ
    PLoS One; 2013; 8(10):e77684. PubMed ID: 24155971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antitumor effects of anlotinib in thyroid cancer.
    Ruan X; Shi X; Dong Q; Yu Y; Hou X; Song X; Wei X; Chen L; Gao M
    Endocr Relat Cancer; 2019 Jan; 26(1):153-164. PubMed ID: 30139768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
    Zhu X; Park S; Lee WK; Cheng SY
    Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Torin2 targets dysregulated pathways in anaplastic thyroid cancer and inhibits tumor growth and metastasis.
    Sadowski SM; Boufraqech M; Zhang L; Mehta A; Kapur P; Zhang Y; Li Z; Shen M; Kebebew E
    Oncotarget; 2015 Jul; 6(20):18038-49. PubMed ID: 25945839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. LncRNA NEAT1 enhances the resistance of anaplastic thyroid carcinoma cells to cisplatin by sponging miR‑9‑5p and regulating SPAG9 expression.
    Yan P; Su Z; Zhang Z; Gao T
    Int J Oncol; 2019 Nov; 55(5):988-1002. PubMed ID: 31485599
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Apatinib Inhibits Angiogenesis Via Suppressing Akt/GSK3β/ANG Signaling Pathway in Anaplastic Thyroid Cancer.
    Jin Z; Cheng X; Feng H; Kuang J; Yang W; Peng C; Shen B; Qiu W
    Cell Physiol Biochem; 2017; 44(4):1471-1484. PubMed ID: 29190616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
    Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
    Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
    [TBL] [Abstract][Full Text] [Related]  

  • 16. miR-148a inhibits self-renewal of thyroid cancer stem cells via repressing INO80 expression.
    Sheng W; Chen Y; Gong Y; Dong T; Zhang B; Gao W
    Oncol Rep; 2016 Dec; 36(6):3387-3396. PubMed ID: 27779717
    [TBL] [Abstract][Full Text] [Related]  

  • 17. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
    Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
    Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combination of SL327 and Sunitinib Malate leads to an additive anti-cancer effect in doxorubicin resistant thyroid carcinoma cells.
    Wang W; Zhou J; Zhao L; Chen S
    Biomed Pharmacother; 2017 Apr; 88():985-990. PubMed ID: 28178630
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells.
    Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
    Endocrine; 2016 Feb; 51(2):274-82. PubMed ID: 26219406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lenvatinib exhibits antineoplastic activity in anaplastic thyroid cancer in vitro and in vivo.
    Ferrari SM; Bocci G; Di Desidero T; Elia G; Ruffilli I; Ragusa F; Orlandi P; Paparo SR; Patrizio A; Piaggi S; La Motta C; Ulisse S; Baldini E; Materazzi G; Miccoli P; Antonelli A; Fallahi P
    Oncol Rep; 2018 May; 39(5):2225-2234. PubMed ID: 29517103
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.